First Patient Enrolled in Merakris-Sponsored VA Clinical Trial
27 juil. 2022 06h30 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 27, 2022 (GLOBE NEWSWIRE) -- The first patient has been enrolled in a Phase II clinical trial – sponsored by Merakris Therapeutics – to measure the safety and...
Merakris CEO To Discuss Dermacyte® Development Program As Part of Advanced Wound Care Summit Panel in July
28 juin 2022 08h00 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 28, 2022 (GLOBE NEWSWIRE) -- About five years ago, the U.S. Food and Drug Administration (FDA) announced plans to toughen its guidelines around the development and...
Study Shows Effectiveness of Merakris’ Wound Care Products
02 juin 2022 07h30 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris...
Study in Modern Optometry Shows Effectiveness Of Merakris Therapeutics’ Eye Product, Opticyte® Matrix
24 mars 2022 15h40 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Opticyte® Amniotic Ocular Matrix, a product of Research Triangle Park-based Merakris Therapeutics, has gotten the attention of a...
Merakris and Dept. of Veterans Affairs Sign CRADA Agreement – Clinical Trial for Dermacyte® Wound Care Product To Begin Soon
08 févr. 2022 06h35 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United...
Merakris Announces Agreement With Miracles In Sight Eye Bank To Supply Opticyte® Repair Grafts to Eye Surgeons
20 juil. 2021 06h30 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., July 20, 2021 (GLOBE NEWSWIRE) -- Research Triangle Park-based biotechnology company Merakris Therapeutics has reached an agreement with Miracles In Sight (MIS) to...
Merakris Therapeutics, Inc. Announces FDA Clearance for Dermacyte® Liquid Clinical Trial
25 mai 2021 09h00 HE
|
Merakris Therapeutics
RESEARCH TRIANGLE PARK, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Merakris Therapeutics, Inc. (Merakris) announced that it has received U.S. Food and Drug Administration (FDA) clearance for a Phase II...